Avalo Therapeutics Operating Income 2014-2024 | AVTX

Avalo Therapeutics operating income from 2014 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Avalo Therapeutics Operating Income 2014-2024 | AVTX

Avalo Therapeutics operating income from 2014 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.8B
Takeda Pharmaceutical (TAK)$42.6B
Sandoz Group AG (SDZNY)$19.5B
Merck (MKKGY)$19.1B
Astellas Pharma (ALPMY)$18.3B
United Therapeutics (UTHR)$16.6B
Summit Therapeutics (SMMT)$14B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12B
Catalent (CTLT)$11.1B
Madrigal Pharmaceuticals (MDGL)$7.6B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$6B
Ionis Pharmaceuticals (IONS)$5.4B
Crinetics Pharmaceuticals (CRNX)$5.2B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Soleno Therapeutics (SLNO)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
NewAmsterdam Pharma (NAMS)$1.9B
Xencor (XNCR)$1.8B
Recursion Pharmaceuticals (RXRX)$1.6B
Evotec AG (EVO)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Harrow (HROW)$1.5B
Indivior (INDV)$1.5B
Guardian Pharmacy Services (GRDN)$1.5B
Ocular Therapeutix (OCUL)$1.4B